BioMarin Pharmaceuticals BMRN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $520.42M+61.5% | $657.24M+156% | $523.88M+155% | ||
| $73.9M-18.9% | $79.56M-17.5% | $82.73M-17.0% | $83.25M-21.7% | $91.15M-13.5% | ||
| $187.17M+3.4% | $181.41M-10.0% | $186.42M-8.8% | $180.64M-13.7% | $181.02M-14.5% | ||
| —— | —— | —— | $116.33M+403% | $84.24M+313% | ||
| $8.05M+166% | $2.62M-21.9% | $2.63M-28.7% | $2.7M-34.4% | $3.03M-27.0% | ||
| —— | —— | —— | —— | $22.86M— | ||
| —— | —— | —— | —— | —— | ||
| $48.1M— | $116.93M— | $133.07M— | —— | —— | ||
| —— | —— | $19.22M— | $25.13M— | —— | ||
| $35.47M-43.9% | $38.57M-47.7% | $74.54M+76.7% | $64.33M+32.9% | $63.19M+47.1% | ||
| —— | —— | $26.42M+35.6% | $13.59M-41.4% | $13.52M-40.3% | ||
| $8.73M+147% | $4.63M+123% | -$19.47M-1,496% | -$19.08M-1,304% | -$18.74M-117,231% | ||
| -$3.67M— | -$8.89M— | —— | —— | —— | ||
| $874.25M+24.8% | $827.99M+44.5% | $913.98M+120% | $766.77M+133% | $700.26M+150% | ||
| $107.19M+40.9% | $103.04M+20.6% | $81.85M-13.7% | $71.86M-26.7% | $76.09M-22.6% | ||
| $292.39M-22.6% | $355.88M-13.3% | $371.14M-24.8% | $417.22M-32.7% | $377.86M-50.9% | ||
| $1.03B+77.3% | $337.8M-46.6% | $449.13M-24.1% | $511.11M-26.1% | $579.29M-25.9% | ||
| —— | —— | —— | —— | -$855.75K— | ||
| $339.52M— | -$414.24M— | -$295.39M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $45.37M-31.7% | $55.97M-27.8% | $58.17M-24.0% | $61.91M-17.7% | $66.39M-11.3% | ||
| —— | —— | —— | —— | —— | ||
| $806.4M— | -$45.55M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.02B+571% | $368.84M+96.5% | $574.66M— | $241.67M— | $301.81M— | ||
| $100.46M+53.7% | $96.21M+68.0% | $91.39M+58.4% | $96.77M+42.3% | $65.36M-8.3% | ||
| $3.89M-46.0% | $4.8M-42.5% | $5.42M-40.2% | $6.38M-31.9% | $7.21M-26.2% | ||
| $8.05M+166% | $2.62M-21.9% | $2.63M-28.7% | $2.7M-34.4% | $3.03M-27.0% | ||
| —— | —— | —— | —— | $22.86M— | ||
| -$21.2M— | -$4.46M— | —— | —— | —— | ||
| -$3.67M— | -$8.89M— | —— | —— | —— | ||
| $8.73M+147% | $4.63M+123% | -$19.47M-1,496% | -$19.08M-1,304% | -$18.74M-117,231% | ||
| —— | —— | —— | —— | -$855.75K— | ||
| $1.03B+77.3% | $337.8M-46.6% | $449.13M-24.1% | $511.11M-26.1% | $579.29M-25.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $4.75M-37.4% | ||
| $767.06M+22.9% | $724.96M+48.7% | $832.13M— | $694.91M— | $624.18M— | ||
| $767.06M+22.9% | $724.96M+48.7% | $832.13M— | $694.91M— | $624.18M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioMarin Pharmaceuticals generate?
- BioMarin Pharmaceuticals (BMRN) generated $874.3M in operating cash flow over the trailing twelve months.
- What is BioMarin Pharmaceuticals's free cash flow?
- After $107.2M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $767.1M over the trailing twelve months, up 22.9% year over year.
- Where does BioMarin Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
